Evidence map›Paper›PMID 20702730›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2010

Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus.

Agneta von Gegerfelt, Antonio Valentin, Candido Alicea, Koen K A Van Rompay, Marta L Marthas, David C Montefiori, George N Pavlakis, Barbara K Felber

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Cytotoxic CD4Frontiers in immunology · 2023
    Review
  2. Article
  3. Article
  4. Acute-Phase CD4Journal of virology · 2018
    Article
  5. Review
  6. Frontiers in immunology · 2018
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Agneta von GegerfeltHuman Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702-1201, USA.
Antonio Valentin
Candido Alicea
Koen K A Van Rompay
Marta L Marthas
David C Montefiori
George N Pavlakis
Barbara K Felber
National Cancer Institute · USUniversity of California, Davis · USCenter for Cancer Research · USDuke University · USFrederick National Laboratory for Cancer Research · US

Funding

ZONA PELLUCIDA PEPTIDES AS IMMUNOCONTRACEPTIVE ANTIGENSP51RR000169 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI HYDE, DALLAS MELVIN · 1985 to 2011
$126.2M
Prevention of AIDSZIABC010350 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2009 to 2025
$30.0M
Immunotherapeutic Approaches for AIDSZIABC010749 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2009 to 2022
$21.6M
Prevention of AIDSZ01BC010350 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2000 to 2008
$3.2M
HIV Molecular Biology and Pathogenic Mechanisms of AIDSZ01BC010750 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2006 to 2008
$919k
Intramural NIH HHS Z01 BC010350Intramural NIH HHS Z01 BC010750NCRR NIH HHS P51 RR000169NCRR NIH HHS RR-00169
6 · The paper itself

Abstract

Indian rhesus macaques infected with the Rev-independent live-attenuated SIVmac239 strains control viremia to undetectable levels, have persistent but low cellular and humoral anti-SIV responses, and show no signs of immune deficiency. To analyze the immune mechanisms responsible for viral control, five macaques infected at day 1 after birth were subjected to CD8(+) cell depletion at 6.7 y postinfection. This resulted in viremia increases to 3.7-5.5 log(10) RNA copies, supporting a role of CD8-mediated responses in the control of viral replication. The rebounding viremia was rapidly controlled to levels below the threshold of detection, and occurred in the absence of SIV-specific CD8(+) T cells and significant CD8(+) T cell recovery in four of the five animals, suggesting that other mechanisms are involved in the immunological control of viremia. Monitoring immune responses at the time of viral control demonstrated a burst of circulating SIV-specific CD4(+) T cells characterized as CD45RA(-)CD28(+)CD95(+)CCR7(-) and also granzyme B(+), suggesting cytotoxic ability. Control of viremia was also concomitant with increases in humoral responses to Gag and Env, including a transient increase in neutralizing Abs against the neutralization-resistant SIVmac239 in four of five animals. These data demonstrate that a combination of cellular responses mediated by CD4(+) T cells and humoral responses was associated with the rapid control of the rebounding viremia in macaques infected by the Rev-independent live-attenuated SIV, even in the absence of measurable SIV-specific CD8(+) T cells in the blood, emphasizing the importance of different components of the immune response for full control of SIV infection.

Indexed as

Lymphocyte DepletionAnimalsAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytotoxicity, ImmunologicEpitopes, T-LymphocyteGenes, envMacaca mulattaSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusUp-RegulationVaccines, AttenuatedViremiaAntibodies, NeutralizingAntibodies, ViralEpitopes, T-LymphocyteSAIDS VaccinesVaccines, Attenuated

Identifiers

PMID20702730
PMCPMC7316374
OpenAlexW2105149642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.